# Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract

> **NCT02366676** · PHASE4 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 105 (estimated)

## Conditions studied

- Recurrent Cystitis

## Interventions

- **DRUG:** hyaluronic acid and chondroitin sulphate

## Key facts

- **NCT ID:** NCT02366676
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-01
- **Final completion:** 2019-10-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2019-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366676, "Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02366676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*